Research Reports

Key takeaways

Glenn Gormley, MD, PhD appointed Class I director and Science and Technology Committee Co-Chairperson effective April 15, 2026.

Helen S. Kim and Oleg Nodelman resigning from Board effective May 20, 2026, not due to disagreements.

Dr. Gormley granted option for 37,866 shares vesting over three years at April 15 closing price.

Annual cash compensation: $45,000 for Board service, $15,000 prorated for Co-Chairperson role.

Dr. Gormley brings extensive pharma leadership from Daiichi Sankyo, Novartis, AstraZeneca.

No family relationships or related-party transactions with Dr. Gormley.

Full analysis

The appointment of Dr. Glenn Gormley strengthens Aktis Oncology's Board with his three decades of biopharmaceutical leadership, including global R&D head at Daiichi Sankyo where he advanced ADC platforms relevant to the company's radiopharmaceutical focus, and prior CMO roles at AstraZeneca and Novartis. His expertise in oncology innovation and clinical development is expected to support upcoming clinical milestones for programs like AKY-1189 and AKY-2519. The resignations of Helen S. Kim and Oleg Nodelman, early Series A investors, mark a transition as the company evolves to a clinical-stage public entity, with the Board expressing gratitude for their foundational contributions over five years. Compensation aligns with the Non-Employee Director Policy, providing market-standard incentives to retain talent.

AKTS · Aktis Oncology, Inc.

Summary

Key takeaways

Full analysis